MeiraGTx Holdings PLCNASDAQ:MGTX
- LAST PRICE6.7700
- TODAY'S CHANGE (%)0.2200 (3.3588%)
- Bid / Lots6.7700/ 17
- Ask / Lots7.3800/ 1
- Open / Previous Close6.6000 / 6.5500
- Day Range
- 52 Week Range
- Volume176,658
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MGTX |
|---|---|---|
| 09:32 ET | 2645 | 6.59 |
| 09:33 ET | 400 | 6.6 |
| 09:35 ET | 770 | 6.6921 |
| 09:37 ET | 1600 | 6.4808 |
| 09:48 ET | 100 | 6.55 |
| 09:51 ET | 200 | 6.6132 |
| 09:53 ET | 1517 | 6.5892 |
| 09:55 ET | 100 | 6.48 |
| 10:02 ET | 100 | 6.525 |
| 10:09 ET | 3447 | 6.6 |
| 10:11 ET | 5000 | 6.605 |
| 10:13 ET | 2698 | 6.65 |
| 10:15 ET | 13729 | 6.69 |
| 10:18 ET | 10590 | 6.695 |
| 10:20 ET | 2200 | 6.71 |
| 10:22 ET | 7002 | 6.6964 |
| 10:24 ET | 2416 | 6.675 |
| 10:26 ET | 3097 | 6.69 |
| 10:27 ET | 100 | 6.685 |
| 10:29 ET | 245 | 6.68 |
| 10:33 ET | 248 | 6.66 |
| 10:36 ET | 200 | 6.68 |
| 10:38 ET | 200 | 6.68 |
| 10:40 ET | 200 | 6.65 |
| 10:49 ET | 888 | 6.71 |
| 10:51 ET | 314 | 6.71 |
| 10:54 ET | 100 | 6.69 |
| 10:58 ET | 100 | 6.7 |
| 11:00 ET | 1400 | 6.74 |
| 11:02 ET | 200 | 6.725 |
| 11:03 ET | 547 | 6.69 |
| 11:05 ET | 100 | 6.7 |
| 11:07 ET | 1208 | 6.715 |
| 11:09 ET | 750 | 6.715 |
| 11:12 ET | 200 | 6.7 |
| 11:14 ET | 1158 | 6.71 |
| 11:21 ET | 654 | 6.69 |
| 11:23 ET | 200 | 6.7 |
| 11:25 ET | 800 | 6.715 |
| 11:30 ET | 100 | 6.71 |
| 11:32 ET | 2700 | 6.71 |
| 11:34 ET | 200 | 6.7 |
| 11:36 ET | 194 | 6.7102 |
| 11:39 ET | 100 | 6.71 |
| 11:43 ET | 100 | 6.705 |
| 11:45 ET | 1473 | 6.755 |
| 11:52 ET | 1100 | 6.76 |
| 11:54 ET | 200 | 6.76 |
| 11:57 ET | 100 | 6.77 |
| 12:01 ET | 100 | 6.755 |
| 12:03 ET | 1940 | 6.73 |
| 12:06 ET | 500 | 6.73 |
| 12:08 ET | 1210 | 6.735 |
| 12:12 ET | 2360 | 6.735 |
| 12:14 ET | 400 | 6.72 |
| 12:15 ET | 600 | 6.72 |
| 12:17 ET | 4231 | 6.655 |
| 12:19 ET | 333 | 6.645 |
| 12:21 ET | 3199 | 6.665 |
| 12:24 ET | 1600 | 6.69 |
| 12:26 ET | 100 | 6.685 |
| 12:28 ET | 4800 | 6.7 |
| 12:30 ET | 700 | 6.695 |
| 12:32 ET | 1400 | 6.7 |
| 12:33 ET | 200 | 6.7 |
| 12:35 ET | 1260 | 6.705 |
| 12:37 ET | 600 | 6.72 |
| 12:39 ET | 2144 | 6.71 |
| 12:42 ET | 469 | 6.715 |
| 12:44 ET | 3260 | 6.76 |
| 12:48 ET | 1222 | 6.77 |
| 12:50 ET | 900 | 6.76 |
| 12:51 ET | 4368 | 6.75 |
| 12:53 ET | 6559 | 6.78 |
| 12:55 ET | 400 | 6.785 |
| 12:57 ET | 4325 | 6.76 |
| 01:00 ET | 17504 | 6.77 |
Nov 24, 2024
Press Release: Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors, from 7:27PM ET on Sunday Nov 24, 2024 by Dow Jones
7:27PM ET on Sunday Nov 24, 2024 by Dow JonesAscentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors, from 7:27PM ET on Sunday Nov 24, 2024 by Dow Jones
7:27PM ET on Sunday Nov 24, 2024 by Dow Jones
Nov 18, 2024
DJ MeiraGTx Holdings Is Maintained at Buy by Chardan Capital, from 5:16PM ET on Monday Nov 18, 2024 by Dow Jones
5:16PM ET on Monday Nov 18, 2024 by Dow Jones
Nov 14, 2024
DJ MeiraGTx Holdings Is Maintained at Outperform by RBC Capital, from 12:11PM ET on Thursday Nov 14, 2024 by Dow Jones
12:11PM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 13, 2024
MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates, from 8:01AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:01AM ET on Wednesday Nov 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
MeiraGTx Holdings PLC | 499.4M | -5.2x | --- |
Verve Therapeutics Inc | 449.6M | -2.3x | --- |
PureTech Health PLC | 507.3M | -7.4x | --- |
Mereo BioPharma Group PLC | 552.3M | 0.0x | --- |
Terns Pharmaceuticals Inc | 499.4M | -5.3x | --- |
Kalvista Pharmaceuticals Inc | 495.2M | -2.8x | --- |
Company Information
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Contact Information
- Headquarters
- 450 EAST 29TH STREET, 14TH FLOORNEW YORK, NY, United States 10016
- Phone
- 646-860-7985
- Fax
- ---
Executives
- Independent Chairman of the Board
- Keith Harris
- President, Chief Executive Officer, Director
- Alexandria Forbes
- Chief Financial Officer, Chief Operating Officer
- Richard Giroux
- General Counsel, Secretary
- Robert Wollin
- Chief Development Officer
- Stuart Naylor
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $499.4M |
|---|---|
Revenue (TTM) | $13.9M |
Shares Outstanding | 78.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.24 |
EPS | $-1.30 |
Book Value | $2.17 |
P/E Ratio | -5.2x |
Price/Sales (TTM) | 35.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,266.97% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
